Special Issue

Choline Kinase as a Therapeutic Target

Message from the Guest Editors

Choline kinase serves as an enzyme integral to the production of phosphatidylcholine a key component of the cell membrane, and, therefore, of cell division. As an established oncogene, overexpression of choline kinase has been correlated with tumor progression and has therefore undergone intensive research as both a therapeutic target and a prognostic marker for many different types of cancer, including childhood versions. Beyond its role in cancer, this enzyme also plays a role in diverse pathologies of inflammatory, bacterial, and parasitic origins and has the potential to serve as a therapeutic target for these diseases as well. In this Special Issue, we will delve into the latest studies that clarify the implications of choline kinase across various pathologies. This exploration will encompass areas such as drug design, basic research, and preclinical investigations, as well as illustrating potential uses for choline kinase modulation for the treatment of diseases that have not yet been explored.

Guest Editors

Dr. Tahl Zimmerman

Food Microbiology and Biotechnology Laboratory, Food and Nutritional Sciences Program, Department of Family and Consumer Sciences, College of Agriculture and Environmental Sciences, North Carolina Agricultural & Technical State University, Greensboro, NC 27411, USA

Prof. Dr. Juan Carlos Lacal

Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas, 28029 Madrid, Spain

Deadline for manuscript submissions

closed (20 June 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/193273

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

